Tackling Chronic Inflammation with Withanolide Phytochemicals-A Withaferin A Perspective

• Główni autorzy: Emilie Logie (Autor), Wim Vanden Berghe (Autor)
• Format: Książka
• Wydane: MDPI AG, 2020-11-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.
• Notes: 10.3390/antiox9111107; 2076-3921
• Keywords: Withaferin A; natural product; inflammation; chronic diseases; therapy; Therapeutics. Pharmacology; RM1-950
• Source: Antioxidants, Vol 9, Iss 11, p 1107 (2020)

Chronic inflammatory diseases are considered to be one of the biggest threats to human health. Most prescribed pharmaceutical drugs aiming to treat these diseases are characterized by side-effects and negatively affect therapy adherence. Finding alternative treatment strategies to tackle chronic inflammation has therefore been gaining interest over the last few decades. In this context, Withaferin A (WA), a natural bioactive compound isolated from <i>Withania somnifera</i>, has been identified as a promising anti-cancer and anti-inflammatory compound. Although the majority of studies focus on the molecular mechanisms of WA in cancer models, recent evidence demonstrates that WA also holds promise as a new phytotherapeutic agent against chronic inflammatory diseases. By targeting crucial inflammatory pathways, including nuclear factor kappa B (NF-κB) and nuclear factor erythroid 2 related factor 2 (Nrf2) signaling, WA suppresses the inflammatory disease state in several in vitro and preclinical in vivo models of diabetes, obesity, neurodegenerative disorders, cystic fibrosis and osteoarthritis. This review provides a concise overview of the molecular mechanisms by which WA orchestrates its anti-inflammatory effects to restore immune homeostasis.